|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Onyx Pharmaceuticals, Inc. (ONXX), a biopharmaceutical company focused on cancer. |
|---|---|
| Transferring Party | Proteolix, Inc., a biopharmaceutical company targeting the proteasome for the treatment of hematological malignancies and solid tumors. |
| Sector | Biopharmaceuticals |
| Date | October 12, 2009 |
| Analysis Proteolix's lead compound, carfilzomib, is a proteasome inhibitor currently in multiple myeloma clinical trials. It is pioneering a new class of potent proteasome inhibitors, offering an important new therapy in oncology. Multiple myeloma is the second most common hematologic cancer and results from an abnormality of plasma cells, usually in the bone marrow. There have been limited treatment options. Deal value -- $276m plus up to $575m in milestone payments. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2010 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |